- Revenue: $2.83 billion, matching the estimate of $2.83 billion.
- Operating Profit: $328 million, surpassing the estimate of $322.5 million.
- Interim Dividend Per Share: 14.4 cents, below the estimate of 17.3 cents.
- Trading Profit: $471 million, above the estimate of $465.3 million.
- 2024 Guidance: Unchanged, with underlying revenue growth expected to be between 5.0% to 6.0% and trading profit margin expected to be at least 18.0%.
- Revenue Growth Expectation: Higher in the second half than the first half of 2024.
- Trading Profit Margin: Expected to be higher in the second half of 2024 than the first half, with a less significant increase compared to 2023.
- Tax Rate Forecast: Tax rate on trading results for 2024 is expected to be between 19% to 20%, assuming no major changes in tax law or unexpected items.
- Performance Highlights: Double-digit trading profit growth and margin expansion due to positive operating leverage and efficiency initiatives.
- Analyst Recommendations: 15 buys, 6 holds, and 1 sell.
A look at Smith & Nephew Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smith & Nephew plc, a company that develops and markets advanced medical devices, has been assigned varying Smart Scores across different factors. While the company shows strong momentum with a score of 4, indicating positive market sentiment and performance, its resilience score is rated lower at 2. This suggests that the company may face more challenges in overcoming economic downturns or industry disruptions compared to its peers. However, the company has average scores of 3 across value, dividend, and growth, showing a balanced performance in these areas.
Looking ahead, the overall outlook for Smith & Nephew seems positive based on its Smart Scores. With a solid momentum score of 4 reflecting strong market trends, the company appears to be in a good position for potential growth. Despite facing some challenges in resilience, the balanced scores in value, dividend, and growth indicate a stable performance in these areas. As Smith & Nephew continues to innovate in orthopaedics, endoscopy, and advanced wound management, it will be interesting to see how these efforts translate into long-term success for the company.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
